Listed

Mesa Laboratories Inc: Form 10-Q for the period ended Jun 30, 2015

Filed with the SEC on Aug 4, 2015 and accepted by EDGAR at Aug 4, 2015, 08:01 ET.

Share

Management's discussion and analysis

As filed, 25,572 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Forward Looking Statements

This report contains information that may constitute "forward-looking statements.” Generally, the words "believe," "expect," "project," “anticipate,” "estimate," "intend," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, "Item 1A. Risk Factors" and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2015, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.

General Discussion

We pursue a strategy of focusing primarily on quality control products and services, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into four divisions across seven physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments. Our Cold Chain Division provides parameter monitoring of products in a cold chain, consulting services such as compliance monitoring, packaging development and validation or mapping of transport and storage containers, and thermal packaging products such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.

Our revenues come from two main sources – products sales and services. Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products and acquisitions. Biological indicator and cold chain packaging products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products, cold chain services and continuous monitoring systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Service demand is driven by our customers’ quality control and regulatory environments, some of which require periodic repair and recalibration or certification of our instrument products and continuous monitoring systems. We typically evaluate costs and pricing annually. Our policy is to price our products and systems competitively and, where possible, we try to pass along cost increases in order to maintain our margins.

Gross profit is affected by our product mix, manufacturing efficiencies and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margins for some of the products have improved. There are, however, differences in gross margins between different product lines, and ultimately the mix of sales will continue to impact our overall gross margin.

Selling expense is driven primarily by labor costs, including salaries and commissions. Accordingly, it may vary with sales levels. Labor costs and amortization of intangible assets drive the substantial majority of general and administrative expense. Research and development expense is predominantly comprised of labor costs and third party consultants.

Year Ending March 31, 2016 Acquisitions

During the year ending March 31, 2016, we completed the following acquisition:

In July 2015, we completed a business combination (the “Infitrak Acquisition”) whereby we acquired all of the common stock of 2396081 Ontario Inc. and its wholly owned operating subsidiary, Infitrak Inc. (collectively “Infitrak”), a company whose business provides consulting, packaging and measuring solutions for cold chain applications.

Year Ended March 31, 2015 Acquisitions

During the year ended March 31, 2015, we completed the following six acquisitions (the “2015 Acquisitions”):

In March 2015, we completed a business combination (the “Früh Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Dr. Früh Control GmbH’s (“Fruh”) business segment associated with the distribution of our biological indicator products.

In February 2015, we completed a business combination (the “Cherwell Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Cherwell Laboratories Limited’s (“Cherwell”), business segment associated with the distribution of our biological indicator products.

In October 2014, we completed a business combination (the “ATI Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of ATI Atlas Limited (“ATI”), a distributor of our biological indicator products.

In October 2014, we completed a business combination (the “PCD Acquisition”) with PCD-Process Challenge Devices, LLC (“PCD”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of PCD’s business segment associated with the sale of process challenge devices (“PCD’s”), which are used for quality control purposes in the field of ethylene oxide sterilization of medical devices.

In April 2014, we completed a business combination (the “BGI Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of BGI, Incorporated and BGI Instruments, Inc., (collectively “BGI”), businesses focused on the sale of equipment used primarily for particulate air sampling.

In April 2014, we completed a business combination (the “Amilabo Acquisition”) whereby we acquired all of the common stock of Amilabo SAS (“Amilabo”), a distributor of our biological indicator products.

General Trends and Outlook

Our strategic objectives include growth both organically and through further acquisitions. During the year ended March 31, 2015, we continued to build our infrastructure to prepare for future growth, including the addition of key personnel to our operations, sales and marketing, research and development, and finance teams. We also invested in upgrading our information systems and intend to continue doing so.

The markets for our biological indicators and cold chain packaging products remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for biological indicators is growing as more countries focus on verifying the effectiveness of sterilization processes.

In general, our instruments products, cold chain services and our continuous monitoring systems are impacted more by general economic conditions than our biological indicator and cold chain packaging products. As a result, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases. However demand for our instruments products, cold chain services and continuous monitoring systems remains strong and we strive to continue to grow revenues going forward.

We are working on several research and development projects that, if completed, may result in new products for both existing customers and new markets. We are hopeful that all of our divisions will have new products available for sale in the coming year.

Results of Operations

The following table sets forth, for the periods indicated, condensed consolidated statements of income data. The table and the discussion below should be read in conjunction with the accompanying condensed consolidated financial statements and the notes thereto appearing elsewhere in this report (in thousands, except percent data):

Three Months Ended June 30, 2015 2014 Change Percent Change
Revenues $18,158 $16,400 $1,758 11%
Cost of revenues 7,017 6,695 322 5%
Gross profit $11,141 $9,705 $1,436 15%
Gross profit margin 61% 59% 2%
Operating expenses
Selling $1,799 $2,063 $(264) (13)%
General and administrative 4,737 3,836 901 23%
Research and development 963 751 212 28%
$7,499 $6,650 $849 13%
Operating income $3,642 $3,055 $587 19%
Net income 2,306 1,881 425 23%
Net profit margin 13% 11% 2%

Revenues

The following table summarizes our revenues by source (in thousands, except percent data):

Three Months Ended June 30, 2015 2014 Change Percent Change
Biological Indicators $7,236 $6,417 $819 13%
Instruments 8,331 7,685 646 8%
Continuous Monitoring 2,591 2,298 293 13%
Total $18,158 $16,400 $1,758 11%

Three months ended June 30, 2015 versus June 30, 2014

Biological Indicators revenues increased as a result of the ATI, PCD, Früh and Cherwell Acquisitions while organic growth was flat.

Instruments revenues increased as a result of the timing of the BGI acquisition and organic growth of seven percent in our existing product lines which was achieved through existing and new customers.

Continuous Monitoring revenues increased as a result of organic growth of 13 percent which was achieved through existing and new customers.

Gross Profit

The following summarizes our gross profit by segment (in thousands, except percent data):

Three Months Ended June 30, 2015 2014 Change Percent Change
Biological Indicators $4,749 $3,784 $965 26%
Gross profit margin 66% 59% 7%
Instruments 5,355 4,927 428 9%
Gross profit margin 64% 64% --%
Continuous Monitoring 1,037 994 43 4%
Gross profit margin 40% 43% (3)%
Total gross profit $11,141 $9,705 $1,436 15%
Gross profit margin 61% 59% 2%

Three months ended June 30, 2015 versus June 30, 2014

Biological Indicators gross profit margin percentage increased as a result of the ATI, PCD, Früh and Cherwell Acquisitions, price increases and volume-based efficiencies associated with revenues growth.

Instruments gross margin percentage was flat as a result of the completion of integration activities associated with the BGI acquisition which was offset by a change in our product and service mix.

Continuous Monitoring gross profit margin decreased primarily as a result of a change in our product and service mix. Our integration activities associated with the division are essentially completed and we are now focused on cost reduction initiatives to stream line the operations. We are hopeful that we will be able to improve the gross profit margin percentage in the future but it is unclear as to how much improvement we will be able to obtain.

Operating Expenses

Operating expenses for the three months ended June 30, 2015 increased as compared to the prior year as follows (in thousands):

Increase (Decrease) Three Months Ended June 30, 2014
Selling $(264)
General and administrative
Amortization 100
Personnel costs 900
ERP system upgrade 170
Other, net (269)
901
Research and development 212
Operating expenses $849

Selling

Three months ended June 30, 2015 versus June 30, 2014

Selling expenses decreased as compared to the prior year primarily due to a reduction in both bad debt expense and personnel costs. As a percentage of revenues, selling expense decreased to 10 percent as compared to 13 percent in the prior period.

General and administrative

Three months ended June 30, 2015 versus June 30, 2014

General and administrative expenses increased as compared to the prior year primarily due to increased amortization and personnel expenses resulting from the Früh, Cherwell, ATI and PCD Acquisitions and increased spending on our ERP system upgrade.

Research and Development

Three months ended June 30, 2015 versus June 30, 2014

Research and development expenses increased as compared to the prior year as a result of the addition of several new product and software engineers to support existing and acquired businesses.

Net Income

Our income tax rate varies based upon many factors but in general, we anticipate that on a go forward basis, our effective tax rate will approximate 35 percent to 37 percent. Otherwise, net income varied with the changes in revenues, gross profit and operating expenses (which includes $1,271,000 of non-cash amortization of intangible assets).

Liquidity and Capital Resources

Our sources of liquidity may include cash generated from operations, working capital, capacity under our Credit Facility and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources include quarterly dividends to shareholders, payment of debt obligations, long-term capital equipment expenditures and potential acquisitions.

Due to continued organic and acquisition related growth, we have outgrown the capacity of our current building in Bozeman, Montana and as a result, we are building a new facility in the same general area. Construction began in July 2015 and we are hopeful that the building will be completed no later than September 30, 2016. During our year ended March 31, 2015 we acquired the related land for $741,000 and we anticipate that the remaining cost of the new facility will be approximately $14,000,000. Following the relocation from our current Bozeman building into the new facility, we expect to be able to sell the current facility for $2,000,000 - $3,000,000 to partially offset the cost of the new building.

We are currently implementing a new ERP system which has required a significant amount of cash. We incurred $175,000 and $993,000, respectively of expense associated with this project for the three months ended June 30, 2015 and the year ended March 31, 2015. Our expectation is that we will go live with our new ERP system during our third quarter ending December 31, 2015. We anticipate that we will incur up to an additional $500,000 to $750,000 for activities necessary to go live and for related post go-live support. In addition, we may incur additional costs associated with software system upgrades.

Working capital is the amount by which current assets exceed current liabilities. We had working capital of $16,277,000 and $14,965,000, respectively, at June 30, 2015 and March 31, 2015.

In February 2012, we entered into a three year agreement (the “Credit Facility”) for a $20,000,000 revolving line of credit (“Line of Credit”) and up to $1,000,000 of letters of credit. Funds from the Credit Facility were used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures.

In April 2014, the Credit Facility was amended to include a $15,000,000 term loan (the “Initial Term Loan”) and to extend the maturity date of the Credit Facility to June 30, 2017.

On July 1, 2015, we further amended our Credit Facility to extend the maturity date to June 30, 2020, increase the Line of Credit to $50,000,000 and establish a new $20,000,000 term loan (the “Term Loan”). The majority of the proceeds from the Term Loan were used to pay down the remaining $12,000,000 balance of the Initial Term Loan.

Under the Line of Credit, indebtedness bears interest at either: (1) LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25%; or (2) the bank’s commercial bank floating rate (“CBFR”), which is the bank’s prime rate adjusted down by 0.5%.

The Term Loan bears interest at LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25% and requires 20 quarterly principal payments (the first due date was July 15, 2015) in the amount of $750,000 with the remaining balance of principal and accrued interest due on June 30, 2020.

The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four quarters of EBIDTA, as defined, of 3.25 to 1.0 through March 31, 2016 and 3.0 to 1.0 thereafter, and a minimum fixed charge coverage ratio of 1.35 to 1.0. We were in compliance with the required covenants at June 30, 2015.

As of July 31, 2015, we had $33,250,000 in outstanding indebtedness and unused capacity under our Credit Facility of $36,000,000.

In April 2015, the SEC declared effective our Universal Shelf Registration Statement which allows us to sell, in one or more public offerings, common stock or warrants, or any combination of such securities for proceeds in an aggregate amount of up to $130,000,000. The terms of any offering, including the type of securities involved, would be established at the time of sale. We have no immediate plans to issue securities under this registration statement.

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We believe that we have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions.

On November 7, 2005, our Board of Directors authorized a program to repurchase up to 300,000 shares of our outstanding common stock. Under the plan, the shares may be purchased from time to time in the open market at prevailing prices or in negotiated transactions off the market. Shares purchased will be canceled and repurchases will be made with existing cash reserves. We do not maintain a set policy or schedule for our buyback program. We have purchased 162,486 shares of common stock under this program from inception through June 30, 2015.

We have been paying regular quarterly dividends since 2003. Dividends per share paid by quarter were as follows:

Year Ending March 31, 2016 2015
First quarter $0.16 $0.15
Second quarter - 0.15
Third quarter - 0.16
Fourth quarter - 0.16

In July 2015, our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on September 15, 2015, to shareholders of record at the close of business on August 31, 2015.

Cash Flows

Our cash flows from operating, investing and financing activities were as follows (in thousands):

Three Months Ended June 30, 2015 2014
Net cash provided by operating activities $2,861 $426
Net cash used in investing activities (1,675) (14,210)
Net cash (used in) provided by financing activities (1,259) 11,409

Net cash provided by operating activities for the three months ended June 30, 2015 increased primarily due to the efficient management of working capital.

Net cash used in investing activities for the three months ended June 30, 2015 resulted from the purchase of $1,675,000 of property, plant and equipment. Net cash used in investing activities for the three months ended June 30, 2014 resulted primarily from the $10,268,000 BGI Acquisition and the purchase of $393,000 of property, plant and equipment.

Net cash used in financing activities for the three months ended June 30, 2015 resulted from the repayment of debt of $1,250,000 and the payment of dividends of $569,000, partially offset by proceeds from the exercise of stock options of $560,000. Net cash provided by financing activities for the three months ended June 30, 2014 resulted from borrowings under our Credit Facility of $18,000,000 and proceeds from the exercise of stock options of $435,000, partially offset by the repayment of debt of $6,500,000 and the payment of dividends of $526,000.

At June 30, 2015, we had contractual obligations for open purchase orders of approximately $10,700,000 for routine purchases of supplies and inventory, which are payable in less than one year.

Under the terms of the Amega Agreement, we are required to pay contingent consideration if the cumulative revenues for our Continuous Monitoring Division for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $10,000,000 and is based upon a sliding scale of three-year cumulative revenues between $31,625,000 and $43,500,000. Based upon both historical and projected growth rates, we recorded $500,000 of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our Continuous Monitoring Division and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in the third quarter of our year ending March 31, 2017.

Under the terms of the PCD Agreement, we are required to pay contingent consideration if the cumulative revenues for our process challenge device business for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $1,500,000 and is based upon a sliding scale of three-year cumulative revenues between $9,900,000 and $12,600,000. Based upon both historical and projected growth rates, we recorded $300,000 of contingent consideration payable which represents our best estimate of the amount that will ultimately be paid. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our process challenge device business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in three annual installments beginning in the third quarter of our year ending March 31, 2016.

Critical Accounting Estimates

Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed consolidated financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2015 in the Critical Accounting Policies and Estimates section of “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.”

Controls and procedures

As filed, 2,866 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of June 30, 2015. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective at June 30, 2015.

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Management evaluated the effectiveness of our internal control over financial reporting based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013.

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of June 30, 2015. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at June 30, 2015. As allowed, this evaluation excludes the operations of acquired entities during the three months ended June 30, 2015 due to the timing of the acquisitions.

Changes in Internal Control Over Financial Reporting

There were no significant changes in our internal control over financial reporting that occurred during the three months ended June 30, 2015, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 439 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2015, under the heading “Part I – Item 1A. Risk Factors.” There have been no material changes to those risk factors.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2015-04-01 to 2015-06-30$7.0mus-gaap:CostOfRevenue
Gross profit3 months2015-04-01 to 2015-06-30$11.1mus-gaap:GrossProfit
Research and development3 months2015-04-01 to 2015-06-30$963.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2015-04-01 to 2015-06-30$3.6mus-gaap:OperatingIncomeLoss
Income tax3 months2015-04-01 to 2015-06-30$1.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2015-04-01 to 2015-06-30$2.3mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2015-04-01 to 2015-06-30$0.63us-gaap:EarningsPerShareDiluted
Basic EPS3 months2015-04-01 to 2015-06-30$0.65us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2015-04-01 to 2015-06-303,686,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2015-04-01 to 2015-06-30$2.9mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Dividends paid3 months2015-04-01 to 2015-06-30$569.0kus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2015-06-30$2.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-06-30$29.3mus-gaap:AssetsCurrent
Total assetsAt period end2015-06-30$117.2mus-gaap:Assets
Current liabilitiesAt period end2015-06-30$13.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-06-30$40.8mus-gaap:Liabilities
Long-term debtAt period end2015-06-30$22.0mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2015-06-30$3.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2015-06-30$76.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001437749-15-014645. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.